Chemical compositions, pharmacological activities, quality control studies of Erycibes plants, and the development of their substitutes

Yu Peng,Hongxun Tao,Yuanyuan Yang,Yuanqing Gao,Hui Ren,Jing Hu,Zhiyong Chen,Ye Li
DOI: https://doi.org/10.1002/ptr.7070
IF: 6.388
2021-03-16
Phytotherapy Research
Abstract:<p><i>Erycibes</i> are members of the <i>Convolvulaceae</i> family, including more than 10 species worldwide that are distributed in tropical Asia. Some <i>Erycibes</i> species have long been used as traditional remedies for rheumatoid arthritis, fever, hepatitis, and liver injury in China and Thailand. A total of 152 compounds from <i>Erycibes</i> plants have been isolated and identified, categorized as flavonoids, coumarins, quinic acid derivatives, lignans, and alkaloids. Coumarins are the characteristic and active constituents of this species, including scopoletin and scopolin. Modern pharmacological studies have shown that the extracts and bioactive components of <i>Erycibes</i> plants exhibit several biological activities, including antiinflammatory, analgesic, hepatoprotective, anti‐gout, antitumor, antioxidation, and other therapeutic effects. However, in recent years, due to destructive exploitation and utilization, some <i>Erycibes</i> plants' natural resources have become rare or endangered. Developing substitutes is a strategy to alleviate the pressure on those endangered medicinal plant resources. To provide a scientific basis for the development and protection of those threatened <i>Erycibes</i> species, this review summarized the current status of the chemical compositions, pharmacological activities, quality control studies, and the development of substitutes for <i>Erycibes</i> plants. In particular, the rationale for use of <i>Porana sinensis</i> currently on the market is discussed.</p>
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?